A glucose monitor without insulin, exercise on a prescription pad, and a heart risk that hides in the liver
Five updates published October 12-18, 2026 translate a glucose-monitor trial in type 2 diabetes without insulin, an ACC statement on prescribing exercise, an AHA statement on two blood thinners after a stent, a review tying liver disease to heart risk, and a PCOS fatty-liver drug trial into questions you can bring to your next appointment.
Five documents published between October 12 and October 18, 2026 touch the three conditions this brief follows. A randomized trial in U.S. primary care tested a continuous glucose monitor in adults with type 2 diabetes who do not take insulin. The American College of Cardiology published a statement asking clinicians to prescribe exercise the way they prescribe a medicine. The American Heart Association set out how a care team should manage the two blood thinners people take after a stent or a heart attack. A review in Circulation makes the case that heart disease is an underrecognized risk for people with liver disease. And a small trial tested a drug for fatty liver in women with polycystic ovary syndrome.
The summaries below are background for your next appointment. Your clinician knows your history, your test results, and your current prescriptions, and treatment decisions belong in that conversation.
Quick view
| Update | What changed | Who may care | Action window | Appointment question |
|---|---|---|---|---|
| A glucose monitor tested in people who take no insulin | A 26-week randomized trial at 22 U.S. primary care practices found that adults with type 2 diabetes not using insulin lowered A1c from 8.8 to 7.2 percent with a monitor, against 8.7 to 8.0 percent with routine care. 1 | Adults with type 2 diabetes managed with pills, whose A1c sits above goal | At your next diabetes visit | "My A1c is above goal and I don't take insulin — would a continuous glucose monitor help me, and what would my insurance cover?" |
| Exercise moves onto the prescription pad | A new American College of Cardiology statement published October 15 asks clinicians to prescribe exercise as a core part of heart care: at least 150 minutes of moderate activity a week, plus resistance training, with benefits starting far below the familiar 10,000-step mark. 2 | Anyone with heart disease or a heart risk factor who has been told to "exercise more" without a plan | This week — pick a starting dose | "What exercise plan fits my condition — how much, how hard, and what should make me stop?" |
| How long two blood thinners last after a stent | An American Heart Association statement published October 13 gathers the current rules: six months of dual antiplatelet therapy after elective stenting, twelve months after a heart attack, shorter courses for people at high bleeding risk, and a stomach-protecting drug for those at risk of gastrointestinal bleeding. 3 | Anyone with a coronary stent or a recent heart attack taking aspirin plus a second antiplatelet drug | Before your next refill or any procedure that would interrupt the drugs | "How long am I supposed to stay on two antiplatelet drugs, and who decides if I stop one early?" |
| The heart risk that travels with liver disease | A review published October 12 in Circulation reports that cardiovascular disease is the leading cause of death in metabolic fatty liver disease, that fibrosis stage 2 or higher carries a 2.5-fold rise in major heart events, and that standard heart-risk calculators underestimate risk in people with liver disease. 4 | Adults with fatty liver, elevated liver enzymes, or cirrhosis, and adults with type 2 diabetes | At your next visit | "I have fatty liver — has my FIB-4 been calculated, and has my heart risk been assessed with my liver in mind?" |
| A drug tested for fatty liver in women with PCOS | A 24-week randomized trial published October 15 in Hepatology tested saroglitazar in 60 women with polycystic ovary syndrome and fatty liver: liver fat fell about 15 percent against a 2 percent rise on placebo, and 36 percent of the treated women reached at least a 30 percent reduction in liver fat, against 8.7 percent on placebo. 5 | Women with polycystic ovary syndrome, who carry a high risk of fatty liver | At your next visit | "I have PCOS — has my liver been checked for fat or scarring, and what would you do with the result?" |
1. A glucose monitor helped people who take no insulin
On October 14 the New England Journal of Medicine published a 26-week randomized trial of continuous glucose monitoring in type 2 diabetes treated without insulin. 1
A continuous glucose monitor is a sensor worn on the arm or belly that reads glucose under the skin every few minutes and sends the number to a phone. Monitors have been shown to help in type 1 diabetes and in type 2 diabetes treated with insulin. 1
This trial asked whether they help people whose diabetes is managed with pills, or with nothing at all. 1
The trial ran at 22 primary care practices in the United States — family practices and clinics, rather than diabetes specialty centers. It assigned 145 adults to use a monitor and 138 to routine care, with ages from 21 to 84. 1
Average A1c fell from 8.8 percent to 7.2 percent in the monitor group over the 26 weeks. In the routine-care group it fell from 8.7 to 8.0 percent, a difference of 0.9 percentage points. 1
Time spent in the target range of 70 to 180 mg/dL was 21 percentage points higher with a monitor. Time below 70 mg/dL was slightly lower in the monitor group, and no one in either group had a severe low. 1
Three limits belong with it. The trial enrolled people whose A1c averaged 8.8 percent, so it says little about someone already near goal. Twenty-six weeks is short. And the trial was funded by Dexcom, which makes glucose monitors. 1
Coverage is the practical question that follows. Insurers set their own rules for who qualifies, and asking before a prescription is written avoids a surprise at the pharmacy. If your A1c is above goal and you manage diabetes with pills, the trial gives you a reason to ask.
Ask at your next visit: "My A1c is above goal and I don't take insulin — would a continuous glucose monitor help me, and what would my insurance cover?"
2. Exercise moves onto the prescription pad
On October 15 the American College of Cardiology published a scientific statement on prescribing exercise for cardiovascular health, in the Journal of the American College of Cardiology. 2 Scientific statements are how the college advises clinicians where the evidence is still evolving. 2
The statement's instruction is that exercise should be prescribed as a core part of heart care, written for the individual patient's condition, fitness, symptoms, medicines, and preferences. 2
The dose it sets is the familiar one, stated plainly: at least 150 minutes a week of moderate aerobic activity, or 75 minutes of vigorous activity, with more volume generally bringing more benefit. Resistance training should complement aerobic exercise for most adults. 2
The statement's most useful message for a reader is about the starting point. The largest gains come when an inactive person begins moving at all. 2
On steps, the statement pushes back on the 10,000-a-day folklore. A pooled analysis of 12 studies covering more than 111,000 people found lower death and cardiovascular event rates at about 2,500 and 2,700 steps a day, with the lowest rates at roughly 8,800 and 7,100.
About 7,000 steps a day is a practical target for many adults, and 10,000 suits people who are already highly active. 2
For someone worried about starting, the statement sets the safety lines. Routine exercise testing before beginning is not required for most people who are asymptomatic or clinically stable, and unnecessary testing can become a barrier. 2
Cardiac rehabilitation keeps its place as first-line treatment after a heart attack, a stent, bypass surgery, or stable angina. 2
For people with hypertension, exercise belongs alongside drug therapy, with one hard rule: skip the session if resting systolic pressure is above 200 mm Hg or diastolic is above 110. 2
Older adults get their own line. For those 65 and older without frailty, the aim is moderate aerobic exercise for at least 30 minutes on most days. 2
On weight, the statement sets limits. Exercise alone is often not an effective way to lose weight, but it helps maintain weight lost through diet, and moderate intensity is the setting that people stay with. 2
Ask at your next visit: "What exercise plan fits my condition — how much, how hard, and what should make me stop?"
3. How long two blood thinners last after a stent
On October 13 the American Heart Association published a scientific statement in Circulation on managing antiplatelet drugs in coronary artery disease. 3
The durations themselves come from the ACC and AHA guidelines already in place. What the statement adds is how the team should carry them out, from the refill to the procedure. 3
Current ACC and AHA guidance, as the statement restates it, sets six months of dual antiplatelet therapy after an elective stent, and at least twelve months after a heart attack, whether or not a stent was placed. 3
Dual antiplatelet therapy means aspirin plus a second drug: clopidogrel, prasugrel, or ticagrelor. After a heart attack, prasugrel or ticagrelor is preferred over clopidogrel unless those two cannot be used. 3
For people whose bleeding risk is high, the statement lists alternatives that the guidelines already allow: a shorter course, a less potent drug, a switch from ticagrelor or prasugrel to clopidogrel within the first month, or a step down to a single antiplatelet drug after one month. 3
People who also take a blood thinner for atrial fibrillation follow a different path. The usual pattern is one to four weeks of all three drugs after a stent, then aspirin stops and one antiplatelet drug continues alongside the anticoagulant. 3
A stomach-protecting proton pump inhibitor is recommended alongside dual antiplatelet therapy for people at high risk of gastrointestinal bleeding. 3
Two everyday hazards sit inside the document. Regular use of nonsteroidal anti-inflammatory drugs should be avoided, because the combination raises both cardiovascular and bleeding risk. 3 And any planned interruption, for surgery or a dental procedure, needs the cardiology team, the prescribing clinician, and the surgeon planning it together rather than one office making the call. 6
The reason the statement leans on teams, pharmacists included, is adherence. Cost, refill gaps, and moves between care settings all interrupt these drugs, and an interruption after a stent is the situation the drugs exist to prevent. 6
Ask at your next visit: "How long am I supposed to stay on two antiplatelet drugs, and who decides if I stop one early?"
4. The heart risk that travels with liver disease
On October 12 Circulation published a review of the cardiovascular complications of chronic liver disease. 4
Its central claim is blunt. In metabolic dysfunction-associated steatotic liver disease, the fatty liver condition once called NAFLD, cardiovascular disease is the leading cause of death. 4
That matters because the condition is common. Pooled estimates put steatotic liver disease at 37.5 percent of the global population, and above 70 percent among people with type 2 diabetes or with overweight or obesity. 4
Risk rises with scarring. People with advanced fibrosis have twice the incidence of cardiovascular disease. In MASH, the inflammatory form of the disease, fibrosis at stage 2 or higher is associated with a 2.5-fold increase in major cardiovascular events and a 1.5-fold increase in death from any cause. 4
The review also explains why this gets missed. The standard heart-risk calculators, including the newer PREVENT equations, were built on general populations and underestimate risk in people with liver disease, particularly with moderate-to-severe steatosis. 4
The tool the review keeps returning to is a score called FIB-4, calculated from age, AST, ALT, and platelet count, all of which sit on routine blood work. A score of 1.3 or higher, or 2.0 or higher from age 65, means the next step is an elastography scan, a liver stiffness measurement, or an enhanced liver fibrosis blood test. 4
The cardiovascular-kidney-metabolic guideline already asks for that score on a schedule: every one to two years for adults with type 2 diabetes or two or more cardiometabolic risk factors, and every two to three years for adults in the earliest metabolic stage. 4
Medicines get a clear answer too. Statins are safe in compensated liver disease and should be prescribed according to heart guidelines; they are generally avoided once cirrhosis has decompensated. 4 Semaglutide and resmetirom are approved for steatohepatitis with stage 2 to 3 fibrosis, and SGLT2 inhibitors remain foundational for heart, kidney, and diabetes indications. 4
The lifestyle numbers are specific. Losing 5 to 10 percent of body weight improves liver fat and inflammation, and losing 10 percent or more improves fibrosis. A Mediterranean diet helps both the liver and the heart, and at least 150 minutes of moderate exercise a week is the standard target. 4
One limit belongs here. This is a review of existing evidence, and it says plainly that the data so far do not establish liver disease as an independent cause of cardiovascular disease. The association is strong and consistent; the causal claim is still open. 4
Ask at your next visit: "I have fatty liver — has my FIB-4 been calculated, and has my heart risk been assessed with my liver in mind?"
5. A drug trial aimed at fatty liver in women with PCOS
On October 15 Hepatology published a 24-week randomized trial of saroglitazar in women who have both polycystic ovary syndrome and fatty liver disease. 5
Polycystic ovary syndrome is a common hormonal condition in women of reproductive age, and fatty liver is common in women who have it. Those women are also underrepresented in liver trials. 5
The trial enrolled 60 women aged 18 to 45 and assigned them at random, double-blind, to saroglitazar 4 mg or a placebo for 24 weeks. The main measure was the percentage change in liver fat, read from an MRI. 5
Liver fat fell 14.8 percent in the treated group and rose 2.0 percent on placebo. After accounting for a difference in starting A1c between the groups, the figures were an 18.9 percent fall against a 6.4 percent rise. 5
A 30 percent or greater drop in liver fat was reached by 36 percent of the treated women and 8.7 percent of those on placebo. Liver enzymes, cholesterol and triglyceride measures, and a liver stiffness-related score also improved. Side effects were comparable between groups and none was serious. 5
The limits are the size and stage of the study. Sixty women over 24 weeks is a signal, and liver fat on a scan stands in for the outcomes that matter, which are cirrhosis, liver failure, and heart events.
Saroglitazar is a phase 2 result, the point at which a drug is tested for whether it works well enough to justify larger trials. 5
What a reader with polycystic ovary syndrome can take from it is smaller and more immediate. Fatty liver develops without symptoms, and a woman whose care has centered on cycles, fertility, and insulin resistance may never have had her liver checked. 5
Ask at your next visit: "I have PCOS — has my liver been checked for fat or scarring, and what would you do with the result?"
Questions to take to your appointment
- "My A1c is above goal and I don't take insulin — would a continuous glucose monitor help me, and what would my insurance cover?"
- "What exercise plan fits my condition — how much, how hard, and what should make me stop?"
- "How long am I supposed to stay on two antiplatelet drugs, and who decides if I stop one early?"
- "I have fatty liver — has my FIB-4 been calculated, and has my heart risk been assessed with my liver in mind?"
- "I have PCOS — has my liver been checked for fat or scarring, and what would you do with the result?"
References
- 1
- 2
- 3
- 4
- 5
- 6
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.